Turning Point Therapeutics Inc (TPTX)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO, CA 92121

Turning Point Therapeutics, Inc. operates as a biopharmaceutical company. The Company designs and develops novel small molecule to treat cancer related diseases. Turning Point Therapeutics serves medical sector in the United States.

View SEC Filings from TPTX instead.
Q2 2019 All Institutions Hedge Funds 1
To trade TPTX now:
Filers who had this stock in their top 10: 3 1 (0.1%)
13F Filers holding this stock: 68 15 (1.55%)
Aggregate 13F shares on 06/30/2019: 18.224 Million 8.164 Million
Aggregate 13F shares on 03/31/2019: 0
Percent change:
Funds creating new positions: 67 15
Funds Adding to an existing position:
Funds closing out their position:
Funds reducing their position:
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TPTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

367.8 Thousand total shares from 4 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

LARSON YI EVP & CHIEF FINANCIAL OFFICER

  • Officer
2,222 2019-09-10 3

COUNTOURIOTIS ATHENA PRESIDENT & CEO

  • Officer
  • Director
22,000 2019-09-10 1

GEORGE SIMEON

  • Director
2,170,327 2019-09-10 1

GLAXOSMITHKLINE PLC

  • Director
2,170,327 2019-09-10 1

CORMORANT ASSET MANAGEMENT, LP

CHEN BIHUA

  • Director
  • 10% Owner
  • FORMER 10% OWNER
3,122,367 2019-08-12 1

GALLAGHER CAROL GILTNER

  • Director
0 2019-07-24 2

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

COUNTOURIOTIS ATHENA - Director - Officer PRESIDENT & CEO

2019-09-10 P 10,000 $45.00 a 22,000 22,000.00 direct

GLAXOSMITHKLINE PLC - Director see footnote

2019-09-10 P 177,777 $45.00 a 2,170,327 2,170,327.00 indirect

LARSON YI - Officer EVP & CHIEF FINANCIAL OFFICER

2019-09-10 P 2,222 $45.00 a 2,222 2,222.00 direct

GEORGE SIMEON - Director see footnote

2019-09-10 P 177,777 $45.00 a 2,170,327 2,170,327.00 indirect

LARSON YI - Officer EVP & CHIEF FINANCIAL OFFICER

2019-08-26 A 312,397 a 312,397 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments